Citation Impact
Citing Papers
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
2013
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Idiopathic pulmonary fibrosis
2017 Standout
Top 10 Challenges in Cancer Immunotherapy
2020
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies
2022
Guillain-Barré syndrome
2016 Standout
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Malignant Gliomas in Adults
2008 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review
2017
Immune checkpoint inhibitors: new strategies to checkmate cancer
2017
Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials
2021
Breast Cancer Statistics, 2022
2022 Standout
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
2008
Bladder Cancer
2020 Standout
Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature
2017
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
2013
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Works of C.H. Barrios being referenced
Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy
2004
1141 POSTER Neutropenia and Thrombocytopenia During Treatment as Biomarkers of Sunitinib Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC)
2011
MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).
2011
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
2019
IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
2019
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
2016